Table 1.
Patient baseline and disease characteristics treated with TTFields concomitant with sorafenib.
| Characteristics | TTFields + Sorafenib (n = 27) |
|---|---|
| Age, years, median (range) | 65 (28–85) |
| Sex, n (%) | |
| Female | 1 (3.7) |
| Male | 26 (96.3) |
| ECOG performance status, n (%) | |
| 0 | 12 (44.4) |
| 1 | 9 (33.3) |
| 2 | 6 (22.2) |
| CTP score | |
| 5 | 9 (33.3) |
| 6 | 4 (14.8) |
| 7 | 10 (37.0) |
| 8 | 4 (14.8) |
| Number of prior treatments, median (range) | 1 (0–6) |
| BCLC stage, n (%) | |
| 0 | 1 (3.7) |
| B | 5 (18.5) |
| C | 21 (77.8) |
| Etiology, n (%) | |
| HBV | 2 (7.4) |
| HCV | 6 (22.2) |
| Alcoholic liver disease | 9 (33.3) |
| Non-alcoholic fatty liver | 3 (11.1) |
| Alcohol and dysmetabolism | 1 (3.7) |
| Alcoholic liver disease and non-alcoholic fatty liver | 1 (3.7) |
| NASH | 1 (3.7) |
| Cirrhosis | 1 (3.7) |
| Other | 1 (3.7) |
| Missing | 2 (7.4) |
| Extrahepatic spread, n (%) | 14 (51.9) |
| Time from diagnosis to enrollment, median (range) weeks | 25.6 (1.9–345.9) |
| Alpha-fetoprotein, median (range) ng/mL * | 80.6 (1.0–4.7 × 106) |
* Data available for 26 patients. BCLC = Barcelona Clinic Liver Cancer, CTP = Child–Turcotte–Pugh; ECOG = Eastern Cooperative Oncology Group; HBV = hepatitis B virus, HCV = hepatitis C virus, NASH = non-alcoholic steatohepatitis; TTFields = Tumor-Treating Fields. Percentage values for patient subsets may not equal 100% due to rounding to the nearest integer.